Cost Effectiveness of Truvada versus Combivir, Both in Combination with Efavirenz (Sustiva)
The objective of the current study, published in the February 2008 issue of Clinical Therapy, was to compare 2 HAART regimens using fixed-dose combination pills in antiretroviral-naïve patients:
• The 48-week cost was 46,464 Euro for the Truvada/efavirenz regimen, versus 56,198 Euro for the Combivir/efavirenz regimen.
• Therefore, savings of 9734 Euro were achieved for each patient treated with Truvada/efavirenz.
• This regimen also produced a gain of 13% of patients with undetectable viral load after 24 months of treatment.
• Consequently, treatment with the Truvada/efavirenz combination would be dominant in therapy for antiretroviral-naive HIV patients.
• Sensitivity tests supported the stability of the base-case analysis.
• The cost-effectiveness ratios were 619.52 Euro for the Truvada/efavirenz regimen versus 906.41 Euro for the Combivir/efavirenz regimen.
Based on these findings, the study authors wrote, "Patients who started treatment of HIV-1 infection with combination Truvada + efavirenz had significantly lower health care resource utilization and overall treatment costs compared with the Combivir + efavirnez combination."
Gilead Sciences Inc., Madrid, Spain.
R Sanchez-de la Rosa, L Herrera L, S Moreno, and others. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Clinical Therapy 30(2): 372-381. February 2008.